Entrada Therapeutics, Inc.
TRDAFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Entrada Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 12, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | 2026-03-31 | 11,011 | $139K | SEC filing |
| Nan Fung Group Holdings Ltd | 2026-03-31 | 49,082 | $619K | SEC filing |
| Trexquant Investment LP | 2026-03-31 | 82,733 | $1.04M | SEC filing |
| CITADEL ADVISORS LLC | 2026-03-31 | 215,018 | $2.71M | SEC filing |
| AMERIPRISE FINANCIAL INC | 2026-03-31 | 70,280 | $887K | SEC filing |
| AQR CAPITAL MANAGEMENT LLC | 2026-03-31 | 79,493 | $1M | SEC filing |
| Nantahala Capital Management, LLC | 2026-03-31 | 159,332 | $2.01M | SEC filing |
| 5AM Venture Management, LLC | 2026-03-31 | 4,056,379 | $51.2M | SEC filing |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2026-03-31 | 526,043 | Not shown | SEC filing |
| Lynx1 Capital Management LP | 2026-03-31 | 211,689 | $2.67M | SEC filing |
| PNC FINANCIAL SERVICES GROUP, INC. | 2026-03-31 | 1,141 | $14.4K | SEC filing |
| MassMutual Private Wealth & Trust, FSB | 2026-03-31 | 186 | $2.35K | SEC filing |
| Allworth Financial LP | 2026-03-31 | 309 | $3.9K | SEC filing |
| Dynamic Technology Lab Private Ltd | 2026-03-31 | 16,474 | $208K | SEC filing |
| CANTOR FITZGERALD, L. P. | 2026-03-31 | 47,000 | $593K | SEC filing |
| Qube Research & Technologies Ltd | 2026-03-31 | 87,453 | $1.1M | SEC filing |
| Bank of New York Mellon Corp | 2026-03-31 | 76,427 | $965K | SEC filing |
| RHUMBLINE ADVISERS | 2026-03-31 | 35,938 | $454K | SEC filing |
| MILLENNIUM MANAGEMENT LLC | 2026-03-31 | 519,356 | $6.55M | SEC filing |
| FRANKLIN RESOURCES INC | 2026-03-31 | 11,102 | $140K | SEC filing |
- Each value is checked against Entrada Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Entrada Therapeutics, Inc.'s share price.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- TWO SIGMA INVESTMENTS, LP: 49,302 shares reported 2025-12-31; 44,602 shares reported 2026-03-31.
- Creative Planning: 22,082 shares reported 2025-12-31; 22,230 shares reported 2026-03-31.
- BAKER BROS. ADVISORS LP: 5,072,730 shares reported 2025-12-31; 5,072,730 shares reported 2026-03-31.
- TCG Crossover Management, LLC: 2,088,392 shares reported 2025-12-31; 2,287,500 shares reported 2026-03-31.
- STATE STREET CORP: 508,789 shares reported 2025-12-31; 533,798 shares reported 2026-03-31.
- MILLENNIUM MANAGEMENT LLC: 497,695 shares reported 2025-12-31; 519,356 shares reported 2026-03-31.
108 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Entrada Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-05-04 · Sethuraman Natarajan: Larger than 81 of the 86 other insider sales of Common Stock on file. SEC filing
- 2025-11-14 · ROCKLAGE SCOTT M: Larger than 85 of the 86 other insider sales of Common Stock on file. SEC filing
- 2025-11-14 · PARMAR KUSH: Larger than 85 of the 86 other insider sales of Common Stock on file. SEC filing
- 2025-06-27 · ROCKLAGE SCOTT M: Larger than 83 of the 86 other insider sales of Common Stock on file. SEC filing
- 2025-06-27 · PARMAR KUSH: Larger than 83 of the 86 other insider sales of Common Stock on file. SEC filing
- 2024-12-10 · GADICKE ANSBERT: Larger than 79 of the 86 other insider sales of Common Stock on file. SEC filing
- 2024-12-10 · MPM BIOVENTURES 2018, L.P.: Larger than 79 of the 86 other insider sales of Common Stock on file. SEC filing
- 2024-08-16 · Dowden Nathan J: Larger than 82 of the 86 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-20 | Zeiher Bernhardt G · Director | Common Stock | P — Open market or private purchase | +5,000 | 5.86 | SEC filing |
| 2026-05-04 | Sethuraman Natarajan · President, Research & Develop. | Common Stock | S — Open market or private sale | −25,907 | 15.39 | SEC filing |
| 2026-05-04 | Dowden Nathan J · President & COO | Common Stock | S — Open market or private sale | −15,000 | 15.33 | SEC filing |
| 2026-04-01 | WENTWORTH KORY JAMES · Chief Financial Officer | Common Stock | S — Open market or private sale | −2,500 | 12.95 | SEC filing |
| 2026-03-10 | WENTWORTH KORY JAMES · Chief Financial Officer | Common Stock | S — Open market or private sale | −11,388 | 13.02 | SEC filing |
| 2026-03-10 | Dowden Nathan J · President & COO | Common Stock | S — Open market or private sale | −11,894 | 13.05 | SEC filing |
| 2026-03-09 | Dowden Nathan J · President & COO | Common Stock | S — Open market or private sale | −3,116 | 13.02 | SEC filing |
| 2026-03-09 | WENTWORTH KORY JAMES · Chief Financial Officer | Common Stock | S — Open market or private sale | −5,089 | 13.00 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-10 | Chapman Gina · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-10 | Radhakrishnan Maha · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-10 | PARMAR KUSH · Director, 10% owner | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-10 | KIM PETER S · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-10 | Zeiher Bernhardt G · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-06-10 | Thistle Mary · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,000 | SEC filing |
| 2026-05-04 | Dowden Nathan J · President & COO | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −15,000 | SEC filing |
| 2026-05-04 | Dowden Nathan J · President & COO | Common Stock | M — Exercise or conversion of derivative security | +15,000 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.